Approval · Notice of Compliance 27459 · 2022
ANAPROX: Notice of Compliance 27459
Issued January 20, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27459
- Date
- January 20, 2022
- Company
- Atnahs Pharma Uk LimitedBasildon, Essex, United Kingdom
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph as per advisement letter. Update to the package insert and conversion of the Product Monograph to 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ANAPROX | Not yet assigned | — |
| ANAPROX DS | Not yet assigned | — |
Medicinal ingredients
- NAPROXEN SODIUM 275 MG per MG
- NAPROXEN SODIUM 550 MG per TAB